Biogen's Mullen earns $20M for a short year

James Mullen only worked at Biogen Idec for the first five months of 2010, but he was well paid for his efforts. Citing a company proxy statement, the Boston Globe's Robert Weisman reveals that Mullen earned slightly more than $20 million in total compensation last year. That's about twice what he earned in 2009, with most of the money coming from stock and options held by the outgoing CEO. Mullen earned $793,846 in salary along with a prorated bonus of $653,400 as he wound down his tenure at the developer. Incoming CEO George Scangos, meanwhile, earned $9.4 million last year after arriving in July. Story

Suggested Articles

After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs as its CMO.

Halozyme CEO Helen Torley discusses how the company stayed alive after its lead program, a treatment for pancreatic cancer, failed in phase 3.

The under-active genes that cause heart problems and poor muscle movement in Down syndrome may also impede the growth of solid tumors, a study found.